Hemp/CBD Compliance

Hemp and CBD supplement compliance operates in the most fragmented and rapidly evolving regulatory landscape in US consumer health. The 2018 Farm Bill defined hemp as Cannabis sativa with not more than 0.3% delta-9 THC on dry weight basis, removed hemp from the Controlled Substances Act, and transferred regulation from DEA to USDA with state production plans. Hemp-derived CBD is therefore not a federal controlled substance provided the source meets the 0.3% threshold. However the FDA holds that CBD is excluded from the dietary supplement definition under FFDCA section 201(ff)(3)(B) because CBD was investigated as a new drug (Epidiolex, GW Pharmaceuticals, FDA approval June 2018) prior to being marketed as a supplement. The FDA has issued warning letters primarily against disease claims, products marketed for children, food and beverage incorporation and untested high-dose products, but has not systematically enforced against the broader CBD supplement market and has requested Congressional action to create a regulatory pathway. State-level divergence is sharp — outright bans (Idaho, Iowa, South Dakota), comprehensive registration regimes (California AB 45, Florida Department of Agriculture, Texas DSHS), delta-8 THC and synthetic cannabinoid derivative bans in over twenty states. Structural commercial constraints include Amazon prohibition of CBD supplements, CBD-specialist payment processor requirement (most national processors decline or impose category-specific underwriting), Meta and Google advertising category restrictions, and CBD-specialist banking. Testing demand is elevated — cannabinoid potency by HPLC quantifying CBD/CBG/CBN/CBC/delta-9/delta-8/THCA/CBDA against label claim and state THC ceiling, per-lot ICP-MS heavy metals (hemp is a bioaccumulator), multi-residue pesticide panels by LC-MS/MS and GC-MS/MS, microbiological including Aspergillus species, mycotoxins, residual solvents, and adulterant screen for synthetic cannabinoids in natural-claim products.